Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study, The Lancet Oncology (2025).
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...
The incredible series of events began in 2021 when Ed learned that his childhood friend, Richard Hall— my cousin—was suffering from kidney failure ... Today, all three men are living healthy ...
It was a historic and record-breaking night during Wednesday's UMass 120-118 triple-overtime victory over Fordham. It was also a very busy night for the referees' whistles. During the nearly four ...
The first phase of the deal will last 42 days, and implementation of the agreement will begin two or three days after its signing. The IDF will withdraw from the Netzarim corridor and all ...
Copyright 2025 The Associated Press. All Rights Reserved. Hundreds marched in Jerusalem on Tuesday against an expected agreement between Israel and Hamas for a ...
A low-cost airline that has rapidly accelerated its route expansion in Connecticut is hitting the brakes, pulling the plug on three ... @courant.com. Some CT restaurants struggle, others are ...
The development of a well-tuned motor control system can be a complex and time-consuming activity that involves many different hardware and software pieces. Industrial motor drives cover a wide range ...
That same day, Weslyn Standard reached out ready to donate her kidney. Standard has three children who were all taught by Griffith during his 30 years of teaching choir. She wanted to say thank ...
Arnold Frolows, one of the founding staff at the original 2JJ and long time music director of triple j, has died. The 74-year-old was diagnosed with pancreatic and liver cancer less than a month ago.
Local kidney donors to conquer three Guatemalan volcanoes Two living kidney donors are gearing up for an extraordinary adventure. Hannah Schmidt tells us more.
There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback